12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial

12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial

Saved in:
Bibliographic Details
Published in:ESMO open Vol. 9; p. 102591
Main Authors: Frueh, M., Soo, R.A., Vervita, A., Cho, B.C., Majem, M., Rodriguez Abreu, D., Callejo Perez, A., Moran Bueno, M.T., Domine Gomez, M., Provencio Pulla, M., Addeo, A., Han, J-Y., Ortega Granados, A.L.O., Ribi, K., Roschitzki-Voser, H., Ruepp, B., Haberecker, M., Dafni, U., Peters, S., Stahel, R.A.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-03-2024
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2024.102591